Advent Pharma Ltd. (DSE: ADVENT)
Bangladesh
· Delayed Price · Currency is BDT 17.20
+0.70 (4.24%)
At close: Nov 14, 2024
Advent Pharma Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2016 |
| Revenue | 568.78 | 558.05 | 530.47 | 503.6 | 534.03 | 601.97 | Upgrade
|
| Revenue Growth (YoY) | 3.00% | 5.20% | 5.34% | -5.70% | -11.29% | 51.99% | Upgrade
|
| Cost of Revenue | 348.35 | 335.14 | 310.31 | 288 | 307.64 | 318.3 | Upgrade
|
| Gross Profit | 220.43 | 222.91 | 220.16 | 215.61 | 226.39 | 283.66 | Upgrade
|
| Selling, General & Admin | 91.3 | 87.55 | 86.78 | 79.18 | 70.98 | 71.23 | Upgrade
|
| Operating Expenses | 91.3 | 87.55 | 86.78 | 79.18 | 70.98 | 71.23 | Upgrade
|
| Operating Income | 129.13 | 135.36 | 133.38 | 136.42 | 155.41 | 212.43 | Upgrade
|
| Interest Expense | -8.23 | -6.63 | -4.11 | -4.9 | -4.44 | -5.41 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.01 | 1.1 | 2.93 | 8.83 | 5.36 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.15 | -0.1 | -0.08 | 0.12 | 1.71 | 1.24 | Upgrade
|
| EBT Excluding Unusual Items | 120.77 | 128.64 | 130.3 | 134.58 | 161.51 | 213.62 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.02 | - | -0.39 | - | -1.66 | Upgrade
|
| Pretax Income | 120.77 | 128.63 | 130.3 | 134.19 | 161.51 | 211.96 | Upgrade
|
| Income Tax Expense | 28.37 | 29.99 | 32.76 | 20.6 | 44.45 | 53.56 | Upgrade
|
| Net Income | 92.4 | 98.64 | 97.53 | 113.59 | 117.05 | 158.4 | Upgrade
|
| Net Income to Common | 92.4 | 98.64 | 97.53 | 113.59 | 117.05 | 158.4 | Upgrade
|
| Net Income Growth | -6.16% | 1.14% | -14.14% | -2.96% | -26.10% | 82.33% | Upgrade
|
| Shares Outstanding (Basic) | 93 | 93 | 93 | 93 | 93 | 93 | Upgrade
|
| Shares Outstanding (Diluted) | 93 | 93 | 93 | 93 | 93 | 93 | Upgrade
|
| Shares Change (YoY) | - | - | - | - | - | 22.72% | Upgrade
|
| EPS (Basic) | 0.99 | 1.06 | 1.05 | 1.22 | 1.26 | 1.70 | Upgrade
|
| EPS (Diluted) | 0.99 | 1.06 | 1.05 | 1.22 | 1.26 | 1.70 | Upgrade
|
| EPS Growth | -6.16% | 1.14% | -14.14% | -2.96% | -26.10% | 48.57% | Upgrade
|
| Free Cash Flow | 13.48 | 2.56 | -11.56 | -3.67 | -42.33 | -68.71 | Upgrade
|
| Free Cash Flow Per Share | 0.14 | 0.03 | -0.12 | -0.04 | -0.45 | -0.74 | Upgrade
|
| Dividend Per Share | 0.200 | 0.200 | 0.200 | 0.196 | - | 0.162 | Upgrade
|
| Dividend Growth | 0% | 0% | 1.99% | - | - | 10.05% | Upgrade
|
| Gross Margin | 38.76% | 39.94% | 41.50% | 42.81% | 42.39% | 47.12% | Upgrade
|
| Operating Margin | 22.70% | 24.26% | 25.14% | 27.09% | 29.10% | 35.29% | Upgrade
|
| Profit Margin | 16.24% | 17.68% | 18.39% | 22.56% | 21.92% | 26.31% | Upgrade
|
| Free Cash Flow Margin | 2.37% | 0.46% | -2.18% | -0.73% | -7.93% | -11.41% | Upgrade
|
| EBITDA | 203.19 | 193.96 | 175.07 | 174.59 | 188.53 | 237.06 | Upgrade
|
| EBITDA Margin | 35.72% | 34.76% | 33.00% | 34.67% | 35.30% | 39.38% | Upgrade
|
| D&A For EBITDA | 74.06 | 58.6 | 41.69 | 38.17 | 33.12 | 24.63 | Upgrade
|
| EBIT | 129.13 | 135.36 | 133.38 | 136.42 | 155.41 | 212.43 | Upgrade
|
| EBIT Margin | 22.70% | 24.26% | 25.14% | 27.09% | 29.10% | 35.29% | Upgrade
|
| Effective Tax Rate | 23.49% | 23.31% | 25.15% | 15.35% | 27.52% | 25.27% | Upgrade
|
| Advertising Expenses | - | 0.19 | 0.18 | 0.15 | 0.11 | 0.33 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.